Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411 | Completed Phase 1

• 2 other identifiers: 04-096AH-101
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and pharmacokinetics (how long a drug stays in the bloodstream and how high the levels of the drug are at different times) of ETI-204 following intravenous (IV-into a vein) injections, and to evaluate the effects that ETI-204 may have on the pharmacokinetics of oral (by mouth) ciprofloxacin, an antibiotic approved by the U.S. Food and Drug Administration (FDA). ETI-204 is an experimental drug (not approved by the FDA) intended to protect against anthrax (a bacterial infection). Approximately 36 male and female healthy volunteers ages 18 to 50 will be in this study. Participation in this study may last up to eight weeks. Volunteers will have a single IV dose of the ETI-204 study drug or placebo (inactive substance, and some participants will also receive ciprofloxacin. They will stay in the Clinical Pharmacology Unit at least 36 hours after the dose.

Conditions

Bacillus Anthracis (Anthrax)

Keywords

anthrax, Bacillus anthracis, monoclonal antibody, ETI-204

Interventions

Ciprofloxacin 500 mg DRUG

ETI-204 (Anthim) DRUG

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects between the ages of 18-50 inclusive at the time of enrollment. In each of the drug cohorts (subgroups), at least two of the subjects must be female.
• The following screening laboratory parameters must be within the normal range: AST, ALT, alkaline phosphatase, hemoglobin, and serum creatinine. No repeat testing is allowed for these analytes. For any other clinical chemistry analyte or CBC (including differential and platelet count) parameter that is outside the normal range, the PI and the sponsor's medical monitor will confer and must agree in writing that the value has no clinical significance before the subject will be allowed to enter the study.
• The values for the following tests at screening are to be:
• G-6-P dehydrogenase - normal HBsAG - negative HBV - negative Anti-HCV - negative Anti-HIV (HIV antibody test) - negative Urine drug screen (including cotinine) - negative
• Female subjects of childbearing potential must agree to practice abstinence or to use a licensed, effective form of birth control (e.g., oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, intrauterine contraceptive device, Depo-Provera®, skin patch, vaginal ring, or cervical cap) for at least 30 days prior to enrollment and for the duration of the study, including the follow-up period. Females using hormonal contraceptives must agree to use at least one other method for at least 30 days prior to enrollment and for the duration of the study, including the follow-up period.
• Female subjects must have a negative pregnancy test.
• No history of hospitalization for illness within the six months prior to study enrollment.
• Non-smoker or ex-smoker. If a subject is an ex-smoker, he/she must not have used nicotine for at least 6 months prior to enrollment. This will be confirmed by a negative urine test for cotinine.
• Able to spend the two days specified in the study schedule confined in a facility under study rules.
• Able to read, understand and sign the Informed Consent form.

You may not qualify if:

• Routine consumption of any medication (prescription or OTC), vitamin, mineral, antacid, or dietary supplement, for one week before and during the study. The sole exception are hormonal contraceptive agents, as detailed above, hormone replacement therapy, and thyroid replacement therapy. Subjects must be specifically reminded that antacids are excluded.
• Blood pressure greater than 145 mm Hg systolic and 95 mm Hg diastolic.
• Contraindication to the use of ciprofloxacin or any quinolone. (Part 2 only).
• Contraindication to the use of any monoclonal antibody.
• Medical condition that in the Investigator's opinion could adversely impact the subject's participation, safety or conduct of the study.
• Subject has taken an investigational medication in the previous three months.
• The subject has a history of drug or alcohol abuse within the past two years.
• The subject is female and plans to become pregnant during the study or the 42 day follow-up period.
• Calculated Body Mass Index (BMI) greater than 35 or less than 18.5.
• The subject has been previously vaccinated with anthrax or has participated in clinical research involving anthrax.
• Any EKG abnormality except for the following:
• Sinus bradycardia in younger, athletic subjects
• Mild first degree A-V block (P-R interval \< 0.23 sec)
• Mild right or left axis deviation
• Incomplete right bundle branch block DMID does not allow for exceptions of eligibility criteria waivers for enrollment.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

Ohio State University

Columbus, Ohio, 43210-1239, United States

Location

MeSH Terms

Conditions

Anthrax

Interventions

Ciprofloxacin; obiltoxaximab

Condition Hierarchy (Ancestors)

Bacillaceae Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH

Study Record Dates

• First Submitted: August 26, 2005
• First Posted: August 30, 2005
• Study Start: October 1, 2005
• Study Completion: March 1, 2006
• Last Updated: August 27, 2010

Record last verified: 2006-07

Locations

US (1)